Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
- 23 April 2010
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (9) , 1548-1554
Abstract
Thalidomide maintenance therapy after stem cell transplantation resulted in increased progression-free survival and overall survival in a few trials, but its role in non-transplant eligible patients with multiple myeloma remains unclear. This study assessed the impact of thalidomide-interferon in comparison to interferon maintenance therapy in elderly patients with multiple myeloma. Of 289 elderly patients with multiple myeloma who were randomized to thalidomide-dexamethasone or melphalan-prednisolone induction therapy, 137 finally completed 9 cycles of induction therapy with stable disease or better and thereby qualified for maintenance treatment. Of these, 128 have been randomized to either thalidomide-interferon or interferon alone. Primary study endpoints were progression-free survival and response rates; secondary endpoints were overall survival, toxicity and quality of life. Thalidomide-interferon maintenance therapy led to a significantly longer progression-free survival compared to interferon (27.7 vs. 13.2 months, P=0.0068), but overall survival was similar in both groups (52.6 vs. 51.4 months, P=0.81) and did not differ between patients aged 75 years or older, or younger patients (P=0.39). Survival after disease progression tended to be shorter in patients on thalidomide-interferon maintenance therapy (P=0.056). Progression-free survival and overall survival tended to be shorter in patients with adverse cytogenetic (FISH) findings compared to the standard risk group but differences were not significant (P=0.084 and P=0.082, respectively). Patients on thalidomide-interferon presented with more neuropathy (P=0.0015), constipation (P=0.0004), skin toxicity (P=0.0041) and elevated creatinine (P=0.026). Thalidomide plus interferon maintenance therapy increased progression-free survival but not overall survival and was associated with slightly more toxicity than maintenance with interferon alone. (ClinicalTrials.gov Identifier: NCT00205751).Keywords
This publication has 21 references indexed in Scilit:
- A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myelomaBlood, 2010
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2006
- Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patientsBlood, 2002
- Interferon-α treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patientsAnnals of Oncology, 2000
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cellsImmunopharmacology, 1998
- Health‐related quality of life assessed before and during chemotherapy predicts for survival in multiple myelomaBritish Journal of Haematology, 1997
- Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosisTubercle and Lung Disease, 1997
- A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patientsBritish Journal of Cancer, 1988
- INTERFERON THERAPY IN MYELOMATOSISThe Lancet, 1979